An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy

[1] Benjamini A(1995)Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc 57 289-300

[2] Hochberg Y(2005)Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line Clin Cancer Res 11 6075-6086

[3] Biliran H(2004)The logrank test BMJ 328 1073-204

[4] Wang Y(2013)Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation Clin Cancer Res 19 194-1870

[5] Banerjee S(2011)Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer J Natl Cancer Inst 103 1859-v115

[6] Xu H(2015)Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up Ann Oncol 21 v103-563

[7] Heng H(2000)The tumor microenvironment as a determinant of drug response and resistance Curr Opin Oncol 12 557-159

[8] Thakur A(2015)Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? BMC Med 13 234-387

[9] Bollig A(2010)Relative expression analysis for molecular cancer diagnosis and prognosis Technol Cancer Res Treat 9 149-361

[10] Sarkar FH(2004)Classifying gene expression profiles from pairwise mRNA comparisons Stat Appl Genet Mol Biol 3 Article19-2827

[1] Benjamini A(1995)Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc 57 289-300

[2] Hochberg Y(2005)Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line Clin Cancer Res 11 6075-6086

[3] Biliran H(2004)The logrank test BMJ 328 1073-204

[4] Wang Y(2013)Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation Clin Cancer Res 19 194-1870

[5] Banerjee S(2011)Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer J Natl Cancer Inst 103 1859-v115

[6] Xu H(2015)Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up Ann Oncol 21 v103-563

[7] Heng H(2000)The tumor microenvironment as a determinant of drug response and resistance Curr Opin Oncol 12 557-159

[8] Thakur A(2015)Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? BMC Med 13 234-387

[9] Bollig A(2010)Relative expression analysis for molecular cancer diagnosis and prognosis Technol Cancer Res Treat 9 149-361

[10] Sarkar FH(2004)Classifying gene expression profiles from pairwise mRNA comparisons Stat Appl Genet Mol Biol 3 Article19-2827